Literature DB >> 28097637

Moving from Patient Advocacy to Partnership: A Long and Bumpy Road.

Durhane Wong-Rieger1,2.   

Abstract

Real-life experiences of grassroots patient organizations across a variety of diseases, countries and contexts have been used to develop a four-mode framework of the transition from patient advocacy to partnership, defined by one axis as individual versus collective action and the other axis as activities 'outside' or 'inside' the system. The four quadrants are labeled as advocacy, activism, reform and broker, and engagement is further refined by whether the participation is 'pushed' by the group or 'pulled' by the system. There are many examples of patient advocacy groups transitioning through the four quadrants; however, depending on other factors of culture, opportunity and their own preferences, groups may work primarily through one or two quadrants.

Entities:  

Mesh:

Year:  2017        PMID: 28097637     DOI: 10.1007/s40271-017-0216-1

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  6 in total

1.  The meaning of patient involvement and participation in health care consultations: a taxonomy.

Authors:  Andrew G H Thompson
Journal:  Soc Sci Med       Date:  2006-12-13       Impact factor: 4.634

2.  An Asia pacific alliance for rare diseases.

Authors:  Durhane Wong-Rieger; William Claxton; Richard Vines; Carmencita Padilla; Kin Ping Tsang; Lucy Hickinbotham
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

3.  Involvement of patient organisations in research and development of orphan drugs for rare diseases in europe.

Authors:  M Mavris; Y Le Cam
Journal:  Mol Syndromol       Date:  2012-09-13

4.  Peer Support and Mentorship in a US Rare Disease Community: Findings from the Cystinosis in Emerging Adulthood Study.

Authors:  Maya Doyle
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

5.  Caregiver preferences for emerging duchenne muscular dystrophy treatments: a comparison of best-worst scaling and conjoint analysis.

Authors:  Ilene L Hollin; Holly L Peay; John F P Bridges
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

6.  Patient involvement in health care decision making: a review.

Authors:  Shaghayegh Vahdat; Leila Hamzehgardeshi; Somayeh Hessam; Zeinab Hamzehgardeshi
Journal:  Iran Red Crescent Med J       Date:  2014-01-05       Impact factor: 0.611

  6 in total
  3 in total

1.  Comment on: "Moving from Patient Advocacy to Partnership: A Long and Bumpy Road".

Authors:  Alain Braillon
Journal:  Patient       Date:  2017-08       Impact factor: 3.883

2.  Building a Bridge Between Genetics and Outcomes Research: Application in Autism (The AutGO Study).

Authors:  Zohreh Talebizadeh; Ayten Shah
Journal:  Patient       Date:  2018-08       Impact factor: 3.883

3.  Practical Considerations in Using Online Modified-Delphi Approaches to Engage Patients and Other Stakeholders in Clinical Practice Guideline Development.

Authors:  Dmitry Khodyakov; Sean Grant; Brian Denger; Kathi Kinnett; Ann Martin; Holly Peay; Ian Coulter
Journal:  Patient       Date:  2020-02       Impact factor: 3.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.